World’s Top-Selling Drug Going Off Patent Means Big Bucks for Middlemen

AbbVie’s Humira has raked in about $200 billion over its lifetime.PHOTO: JOE BUGLEWICZ FOR THE WALL STREET JOURNAL

As AbbVie’s Humira faces copycat biologics, the biggest beneficiaries will be the middlemen negotiating and dispensing the drugs such as Cigna and CVS.

Continue reading World’s Top-Selling Drug Going Off Patent Means Big Bucks for Middlemen